Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Amgen

AMGN

----

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile Weekly ReviewWeekly Review

LongbridgeAI

Weekly Recap | Amgen +7.51%, Phase 3 Sjogren's trial hits endpoint
Weekly Review·Sep 26 at 05:57 AM
AMGN+1.32%
Weekly Recap | Amgen +2.2%, most brokers rate it hold
Weekly Review·Sep 19 at 05:33 AM
AMGN+1.32%
Weekly Recap | Amgen -13.7%, most brokers rate it hold
Weekly Review·Sep 12 at 05:55 AM
AMGN+1.32%
Weekly Recap | Amgen +1.11%, closing in on record highs
Weekly Review·Sep 5 at 06:11 AM
AMGN+1.32%
Weekly Recap | Amgen -1.57%, Tezspire Phase 3 hits endpoints
Weekly Review·Aug 29 at 05:07 AM
AMGN+1.32%
Weekly Recap | Amgen +5.81%, closing in on record highs
Weekly Review·Aug 22 at 04:34 AM
AMGN+1.32%